*Eli Lilly and Company
∥VA HSR&D Center of Excellence for Implementing Evidence-Based Practice, Indiana University
¶Regenstrief Institute Inc.
**PharmaNet/i3, Indianapolis, IN
†Seattle Rheumatology Associates
‡Division of Rheumatology Research, Swedish Medical Center
§Department of Internal Medicine, University of Washington School of Medicine, Seattle, WA
#Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI
††Kaiser Permanente, Escondido, CA
‡‡INC Research, Raleigh, NC
X.P., R.L.R., D.F., and M.W. are employees of and/or shareholders in Eli Lilly and Company (Indianapolis, IN). D.A.W. is a consultant for Eli Lilly and Company, Forest Pharmaceuticals, Pfizer, Jazz Pharmaceuticals, and Bristol Meyers Squibb. Y.C. is an employee of PharmaNet/i3. B.M. is an advisor for NeurogesX. P.M. receives research funding and consulting fees and is an honoraria speaker for Eli Lilly and Company, Forest Pharmaceuticals, and Pfizer. D.H. is a medical writer with INC Research. The REFLECTIONS study was sponsored by Eli Lilly and Company or one of its subsidiaries. K.K. declares no conflict of interest.
Reprints: Xiaomei Peng, MD, PhD, Eli Lilly and Company, Indianapolis, IN 46285 (e-mail: [email protected]).
Received July 26, 2013
Received in revised form February 17, 2014
Accepted January 21, 2014